Mikhail (Misha) Blagosklonny Oncotarget

Altmetric Score for Oncotarget Publications Provides Vital Insight, Mikhail (Misha) Blagosklonny says

Mikhail Blagosklonny Oncotarget

When it comes to modern medicine, it’s impossible to understate the importance of accuracy. Researchers who are publishing papers on pressing issues must be held to a high standard. The problem is that research outputs can live online and be passionately discussed without ever being thoroughly vetted. Mikhail (Misha) Blagosklonny of Oncotarget knew that a better option had to exist. That’s why Oncotarget, a weekly oncology-focused research journal that was established in 2010, uses easy-to-understand Altmetric scores to shine more light. Authors and readers can now gauge publications alongside Altmetric Article Reports, which provides “real-time feedback that contain a summary of data regarding the online engagement relating to a particular publication.” On its website, Oncotarget has released the list of publications with the score higher than 100 and included these reports, which we will explore below. Mikhail (Misha) Blagosklonny of Oncotarget is proud of this offering and hopes that it helps those with a vested interest in oncology.

“A diagnostic autoantibody signature for primary cutaneous melanoma” carries an Altmetric score of 594. The 2018 study was published by Oncotarget and created by experts from Edith Cowan University, Hollywood Private Hospital, St. John of God Hospital, Dermatology Specialist Group and The University of Western Australia. As the introduction to the study states, “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer,” but the silver lining here is that melanoma “is curable by surgical excision in the majority of cases, if detected at an early stage.”

The paper carries an Altmetric score of 594. Mikhail (Misha) Blagosklonny of Oncotarget knows that readers will want to know what exactly this means. According to the Altmetric website, the number shows “how many people have been exposed to and engaged with a scholarly output.” The melanoma paper, for example, was cited in news articles an impressive 69 times. It was noted in two online blogs, 25 “tweets” on Twitter and on one Facebook page post. Under the headline “New blood test could detect skin cancer early,” FOX23 in Tulsa, Oklahoma took the core content of the study from Australia and shared it with viewers on July 20, 2018.

Another top study from Oncotarget’s list is, “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot,” has a score of 476. This is broken down into 60 news stories from 59 outlets, one online blog post and a half-dozen mentions on Twitter. While the majority of the public may only ever be exposed to a brief overview, those who come to Mikhail (Misha) Blagosklonny and Oncotarget for scientific facts will appreciate these new ratings. Oncotarget is proud to be able to offer web visitors this level of information, as it increases dependability and trust.